TSH secretion is decreased by both T4 and T3. This negative feedback control of TSH secretion has been correlated with an increase in pituitary nuclear T3 content, and it is not clear whether T4 exerts its effect directly on the thyrotroph or after its deiodination to T3. However, levels of the pituitary enzyme catalyzing T4 to T3 conversion, 51)-II, are decreased in the presence of an increased amount of T4. Thus, it is unclear why the thyrotroph would have a mechanism for modulating the production of T3, if T3 is, in fact, the sole bioactive signal providing negative feedback inhibition.
Introduction
Thyrotropin (TSH)1 regulates the synthesis and secretion of thyroxine (T4) and triiodothyronine (T3) from the thyroid gland. Pituitary TSH secretion is stimulated by thyrotropin releasing hormone (TRH), and decreased by other hypothalamic factors, including dopamine and somatostatin (1) . Thyroid hormones play a major role in regulating TSH secretion.
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1. Abbreviations used in this paper: 5'D-II, type II 5' deiodinase; T3, triiodothyronine; T4, thyroxine; TRH, thyrotropin-releasing hormone; TSH, thyrotropin; TTR, transthyretin.
In thyroidectomized rats, the administration of physiologic replacement doses of L-T3 decreases serum TSH by -50% in 2 h, and a similar decrease is seen after the administration of L-T4 (2, 3). Silva and Larsen reported that, following the intravenous administration of 70 ng L-T3/l00 g body weight or a 10-fold higher amount of T4, the fall in serum TSH was associated with a rise in the percentage of T) bound to pituitary nuclear receptors (3) . This led to the suggestion that T4 exerts its inhibitory effect on TSH secretion primarily after its deiodination to T3.
This idea was further supported by a number ofsubsequent findings. First, pituitary TSH suppression was dependent upon nuclear T3 content and serum T3 concentration (4) . Second, the simultaneous administration of replacement doses of L-T3
and L-T4 doubled the pituitary nuclear T3 content and augmented the decrease in serum TSH beyond that ofL-T3 administration alone (4) . Furthermore, the administration of iopanoic acid, a potent inhibitor of T4 to T3 conversion, prevented the T4 induced decrease in TSH secretion in thyroidectomized rats (5, 6) . lopanoic acid was also found to block the effect ofT4 on TRH-induced TSH secretion in euthyroid rats (7) . In intact rats, Emerson et al. reported that serum T3 appears to more closely correlate with serum TSH levels than serum T4 (8 concentration rapidly decreases 5D-II activity (11) (12) (13) (14) (15) (16) . This would appear paradoxical in a system thought to respond in a negative-feedback fashion, since the intracellular concentration of T3, the bioactive signal, would be expected to remain constant over a wide range of T4 concentrations. (-2.5 Ci/Mmol) 1 h before the study, using a modification of the method of Silva et al. (9) . At time 0, group I rats were given i.p. ketamine anaesthesia and sacrificed by aortic exsanguination. Group II rats were given 40 mM NaOH vehicle, and group III rats were given EMD 21388 (2 Amol/100 g i.p.). These two groups were sacrificed 1 h later. Rats were perfused with 60-90 ml of saline. Pituitaries and 0.5 g liver were harvested and homogenized in buffer containing 10 mM Hepes and 10 mM iopanoic acid. Radioactivities in aliquots of serum, liver, and pituitary homogenates were measured in a gamma well counter (Autogamma 5000; Packard Instrument Co., Inc., Arlington Heights, IL). Corrections for decay, energy cross-over, and background were made for both isotopes. Tissue T4 and T3 content were analyzed using descending paper chromatography in a solvent system containing 1:5:6 hexane, t-amyl alcohol, and 2N NH40H (20) . Bands ofT4 and T3 were identified by staining with deazotized sulfanilic acid (Pauly's reagent) and iodine was identified with palladium chloride stain. Each T3 and T4 band was cut, counted, and the percentage of total counts was determined by dividing the counts for each isotope in both the T3 and T4 bands by the total counts present on each paper strip. The percentage oftotal counts was then multiplied by the counts present in a milligram of tissue, and expressed as a percent of the total counts of each isotope administered.
In the second set of experiments, group I rats were treated with 40 mM NaOH vehicle i.p. Group II rats received EMD 21388 (2 Mmol/ 100 g i.p.), and group III animals received sodium salicylate (30 mg/ 100 g p.o.). All rats were sacrificed 1 h later by decapitation and trunk blood and pituitaries were collected. Serum was assayed for TSH, total T4, total T3, and free T4. Pituitaries were immediately placed in liquid nitrogen, and later homogenized in 800 ,l of a buffer containing 250 mM sucrose, 20 mM Hepes, 1 mM EDTA, and 1 mM DTT, pH 7.0, just before measuring 51)II activity.
In the third experiment, rats were treated with either 40 mM NaOH vehicle or EMD 21388 (2 ,gmol/100 g i.p.) and sacrificed 1 or 2 h later.
Trunk blood was collected, and serum was assayed for TSH.
Assays. Serum T4 and T3 were measured by RIA as previously described (21) . Serum TSH concentrations were measured by RIA using materials kindly supplied by the National Institutes ofDiabetes, Digestive and Kidney Diseases National Hormone and Pituitary Program, National Institutes of Health, Bethesda, MD. All three hormones were measured in duplicate, in random order, and in the same assay for each experiment. The intraassay coefficients of variation were: T4, < 1%; T3, <5%;andTSH, <1%.
Salicylate levels were determined by a modification of Trinder's method (22) in the serum of salicylate-treated rats, and in equilibrium dialysis buffer after an 18-h incubation with serum containing 2.1 mM sodium salicylate. Percent free T4was measured in duplicate by equilibrium dialysis of undiluted serum at 370C for 18 h as described previously (21) , and the free T4 concentration was calculated as the product of total T4 and percent free T4.
To assess whether a significant concentration of"free" EMD 21388 could be present in vivo and available to cells, we used the ability of EMD 21388 to displace T4 from serum as an index of "free" flavonoid. In the first experiment, increasing quantities of EMD 21388 were added to serum aliquots, creating concentrations of 0-5 mM. In the second experiment, rats were treated with either 2 gmol/100 g or 4 Mmol/100 g EMD 21388 intravenously, sacrificed in 3 min, and trunk blood was obtained. Each serum sample was dialyzed against an equal volume of phosphate buffer for 18 h at 37°. After dialysis, the dialysate was added to an equal volume of fresh normal rat serum, and this mixture was incubated with tracer [1251]-T4 for 30 min. 50 y1 aliquots of each incubation mixture were loaded onto nondenaturing PAGE gels and run for 5 h at 140 V in recirculating 0.02 M phosphate buffer (23) . PAGE-gels were dried and exposed for radioautography for 24 h, and the quantity of radiolabeled T4 bound to TTR was determined by counting the labeled TTR spot and expressing it as a percentage ofthe total counts in that aliquot. Statistical analysis. All data are presented as the mean±SE. Data were analyzed using one way analysis of variance (ANOVA) and Student-Neumann-Keuls multiple comparisons test (SNK), or analysis of covariance, where appropriate.
Results
Effect ofEMD 21388 on the kinetics ofradioiodine-labeled T3 and T4. The ratio of pituitary to serum 1251 counts in the control group at time zero (0.23+0.02) was not different from that in the NaOH-treated group at 60 min (0.20±0.02), indicating that the rats were in equilibrium at the time ofthe experiment. The 1251 pituitary to serum ratio in the EMD 21388-treated group, however, was approximately double that of either control group (0.47±0.06, P < 0.05). (Table I ).
The content of hepatic radioiodine-labeled iodothyronines displayed a similar pattern (Table I) . Again, the liver to serum ratio of 1251I was markedly higher in the EMD 21388 treatment group than in either of the control groups. To ensure an optimal estimation ofpituitary 5D-II activity, we measured the rate of 5D-II activity under reaction conditions that showed linear production of T3 at T4 concentrations approximately two-and fourfold greater than those estimated to be present in the pituitary. T3 production was linear for up to 40 min (data not shown) and the 5D-II activity carried out at 100 and 200 pM ['25I]-T4 is shown in Fig. 1 . EMD 21388 and salicylate administration significantly decreased pituitary 5D-II activity at both substrate concentrations, and greater enzyme activity was present in all groups using 200 pM T4. This suggests that the similar levels of pituitary T3 content seen in all groups in the first set of experiments were due to decreased enzyme activity, and not to a saturation of enzyme capacity.
Determination offree EMD 21388 activity in serum. When EMD 21388 was added to serum in increasing concentrations and then subject to equilibrium dialysis in duplicate, the percentage of [125I]-T4 bound to TTR in normal serum mixed with dialysate is shown in Fig. 2 . In rats given 2 or 4 gmol EMD 21388/100 g body wt intravenously, sacrificed 3 min later, there was no evidence of "free" EMD 21388 activity.
(57.5±1.6% in rats treated with 4 Amol EMD 21388/100 g body wt; 58.0±1.1% at 2 ,umol/100 g, vs. 55.7±1.5% in controls; 4 rats per group, P = NS).
Effect of salicylate added in vitro on pituitary S'D-II. To determine whether sodium salicylate was a direct inhibitor of 5D-Il, we assayed aliquots ofnormal pituitary homogenate for 5D-II activity in the presence of 0, 2, and 10 mM sodium salicylate. The activities in triplicate samples were 47.0, 65.6, and 57.1 fmol 125I released-mg protein-' h-, respectively (NS). Because the serum salicylate concentration in animals treated with 30 mg salicylate/100 g body wt was 34.2 mg/ dl± 1.0 (2.1 mM), it is clear that this administered dose ofsalicylate does not directly inhibit enzyme activity.
Effects ofEMD 21388 and salicylate on serum TSH, total T74, free T4, and total T3 concentrations. Table II illustrates the serum TSH and thyroid hormone levels in the three groups. The decrease in TSH at 1 h in the EMD 21388-treated group, although not statistically significant, was similar to that previously reported (18) . The serum TSH concentration was also slightly lower in the salicylate-treated group. In both treatment groups there was a significant decrease in the serum total T4 concentration compared to the control group. There was a significant increase in the percent free T4 in the EMD 21388- treated group due to the inhibition of T4 binding by TTR, and thus, a less pronounced but still highly significant increase in the serum free T4 concentration. Salicylate administration has been reported to increase the percent free T4 measured by equilibrium dialysis (24) , and the percent free T4 was significantly higher using this technique (salicylate-treated, 0.051±0.003%, vs. control, 0.032±0.002%, P < 0.05). However, we established in a separate experiment, that -70% ofthe serum salicylate is present in the dialysate at equilibrium, and, therefore, equilibrium dialysis cannot accurately reflect the percent free T4 present in vivo. Thus, the free T4 concentration cannot be calculated. It is likely, however, that the serum free T4 concentration in these rats is increased because Larsen has reported that salicylate, when added to human serum at a concentration of 30 mg/dl, doubles the free T4 concentration as measured by an ultrafiltration technique (25) . Serum TSH concentrations I and 2 h after administration of EMD 21388. To demonstrate that the decrease in serum TSH becomes more pronounced over time after EMD 21388 administration, rats were treated with EMD 21388 and serum (16) . Finally, Lum and co-workers have suggested that 5'-deiodinase activity is autoregulated in man, being reduced when serum T4 concentration is elevated, and increased in the presence of a lower T4 value (28) . The present study demonstrates that in euthyroid rats, the basal activity of 5'D-II can be decreased by -25% in 1 h by an increase in pituitary T4 content without the administration of pharmacologic doses of L-T4.
We have also demonstrated that, in the absence of an increase in intrapituitary T3 levels, TSH begins to decrease at 1 h and decreases even further 2 h after EMD 21388 administration. Because previous data indicate that EMD 21388 has a low affinity for the T3 nuclear receptor (29) , and the intracellular T3 that we measured is in dynamic equilibrium with nuclear T3, there is no reason to expect a difference in T3 nuclear receptor occupancy between EMD 21388-treated and control rats. Therefore, basal TSH secretion may decrease independently of the T3 nuclear content.
The importance ofT3 in inhibiting TSH release is clear and has been reported to be more important than T4. Hypothyroid rats treated with iopanoic acid (which blocks both intrapituitary and systemic T4 to T3 conversion) have a lower pituitary nuclear T3 content than control rats, and TSH secretion is not decreased in response to an intravenous bolus of T4 (5). Additionally, T4 does not inhibit the TRH-induced increase in TSH secretion after pretreatment with iopanoic acid (7) . Furthermore, Emerson et al. have recently reported that serum T3 concentrations are more positively correlated with TSH secretion than serum T4 concentrations under physiological conditions (8) . Therefore, it is possible that a critical percentage of nuclear T3 receptors must be occupied to suppress TSH secretion and maintain a basal secretory rate in the euthyroid rat. However, we have now demonstrated that elevations in pituitary T4 content may decrease basal TSH secretion without an associated increase in pituitary T3 content.
It is important to note, however, that thyrotrophs constitute only -10% of the euthyroid pituitary (30), and we may not be observing an accurate reflection of 5D-II activity and iodothyronine content in these cells. Studies of enriched pituitary cell pools have shown that, while under hypothyroid conditions, thyrotrophs have less 5'-D activity than other anterior pituitary cell types, T3 replacement induces a similar, lower level ofactivity in all cell pools (31) . This may indicate that the 5D-II may be less substrate-regulated in the thyrotroph than in other cell types, and it is possible that proportionately more thyrotroph-derived T3 is available to its nucleus when pituitary T4 content is elevated. Alternatively, the thyrotroph may be dependent, in a paracrine fashion, on T3 generated by other pituitary cell types. When T3 availability decreases within the pituitary, TSH secretion is stimulated. However, when T4 content increases, T3 production is blunted in other cell types such as lactotrophs and somatotrophs, and these cells are protected from increased amounts of T3 generated by unchecked local conversion. Under these conditions the total pool of T3 available to the thyrotroph is not different from the euthyroid state, but an additional signal for suppressing TSH secretion, T4, remains intact.
In summary, we have demonstrated that an acute elevation in serum free T4 concentration can increase pituitary (and liver) T4 content, and can rapidly decrease the activity of pituitary 51)-II. Pituitary T3 content does not change and, despite this, TSH secretion decreases. These results suggest that T4 may have an effect on TSH secretion independent of its conversion to T3, and may explain how TSH secretion can decrease in the presence of a decrease in 5D-II activity.
